Skip to main content
Midas Edge

Vistagen Therapeutics, Inc.

For the period ended May 12, 2026. Filed May 12, 2026.

View on SEC.gov

About this filing

A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.

May 12, 2026 · Filed May 12, 2026

Use the contents to explore the available documents and sections.

VTGN$0.16-0.8%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

EX-99.1 · References:

References:

  1. Lappalainen, J et al. (2023). A Phase 3 Open-label Safety Trial of Fasedienol (PH94B) Nasal Spray in the Treatment of Anxiety in Adults with Social Anxiety Disorder (SAD). American Society of Clinical Psychopharmacology (ASCP) 2023 Annual Meeting.

  2. Liebowitz MR, Hanover R, Draine A, Lemming R, Careri J, Monti L (2016). Effect of as‐needed use of intranasal PH94B on social and performance anxiety in individuals with social anxiety disorder. Depress Anxiety 33: 1081-1089.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.